Effect of phosphatidylcholine on lymphatic drainage and fluid loss from the peritoneal cavity of sheep  by Yuan, Zheng-Yi et al.
Kidney International, Vol. 46 (1994), pp. 520—526
Effect of phosphatidyicholine on lymphatic drainage and fluid
loss from the peritoneal cavity of sheep
ZHENG-YI YUAN, HELEN RODELA, JOHN B. HAY, DIMITRIOS G. OREopouLos, and MILES G. JOHNSTON
Trauma Research Program, Sunnybrook Health Science Centre; University of Toronto, Departments of Pathology, Immunology, Su'eiy, and Medicine,
and Division of Nephrology, The Toronto Hospital, Toronto, Ontario, Canada
Effect of phosphatidylcholine on lymphatic drainage and fluid loss from
the peritoneal cavity of sheep. The purpose of this investigation was to test
the hypothesis that phosphatidyicholine enhances net ultrafiltration by
decreasing lymphatic drainage of the peritoneal cavity. Twelve sheep were
used in this study. Six animals received 50 mI/kg intraperitoneal infusions
of Dianeal5 4.25% (490 mOsm/liter) and six received similar volumes of
premixed phosphatidylcholine-Dianeal® (510 mOsm/liter). Labeled albu-
min (25 Ci '251-human serum albumin) was added to the dialysate as a
lymph flow marker. Lymph drainage of the peritoneal cavity was estimated
from the appearance of the intraperitoneally administered tracer in the
blood. Net ultrafiltration was significantly enhanced by phosphatidylcho-
line at each hour up to 6 hours post-infusion, and over this period reached
30.3 3.8 mI/kg in the phosphatidyicholine animals compared to 12.2
2.1 mI/kg in the control group. Phosphatidyicholine treatment decreased
the volume removed by lymphatics; by six hours 5.5 1.1 mI/kg in the
animals receiving phosphatidyicholine, and 10.3 1.0 mI/kg in the control
group was drained as lymph. Fluid loss (estimated from the tracer
disappearance from the peritoneal cavity) was slightly less in the phos-
phatidylcholine-treated animals, averaging 15.8 1.6 in this group versus
16.8 1.7 mI/kg in the control sheep. However, these differences were not
significant. Phosphatidylcholine significantly increased transcapillary ul-
trafiltration (estimate of volume movement into peritoneal cavity without
fluid loss) from 27.6 1.5 mI/kg in the controls to 43.8 3.4 mI/kg in the
animals receiving phosphatidyicholine. In summary, the inhibitory effect
of phosphatidyicholine on lymph drainage may not contribute significantly
to the enhanced net ultrafiltration, since total fluid loss from the perito-
neal cavity was approximately the same in phosphatidylcholine-treated
and untreated groups. We conclude that the main effect of phosphatidyl-
choline in sheep is to facilitate the movement of liquid from the blood into
the peritoneal cavity.
Since Grahame et al [1] demonstrated the presence of phos-
phatidyicholine in peritoneal effluent and other groups reported
that the level of phosphatidylcholine was significantly lower in
CAPD patients with poor ultrafiltration and peritonitis [2—4],
interest in the role of phosphatidyicholine in the transport of
water and solutes in peritoneal dialysis has developed. Phosphati-
dyicholine has been administered into the peritoneal cavity with
the dialysis solution in the hopes of facilitating ultrafiltration. The
results have been promising [2, 5—7]. The mechanism by which
phosphatidyicholine increases ultrafiltration is unknown. How-
ever, it is generally believed that this agent either increases
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transcapillary transport of water and solutes [8] or inhibits pen-
toneal lymphatic drainage [5, 9].
In this report we investigated the effects of phosphatidyicholine
on lymphatic drainage of the peritoneal cavity in sheep. Lymph
drainage pathways and measurements of lymph flow from the
peritoneal cavity in this species have been studied extensively
[10—15]. We provide evidence that phosphatidyicholine enhanced
net ultrafiltration. While phosphatidyicholine depressed lym-
phatic drainage, it appeared to exert its effect on peritoneal
volumes largely by increasing the capillary transport of fluid into
the peritoneal cavity.
Methods
Solutions and tracer
Radiolabeled albumin ('25I-human serum albumin solution 2.5
pCi/mg, 10 mg) was used as the lymph flow marker. This tracer
was purchased from Frosst (Kirkland, Quebec, Canada). The
premixed phosphatidyicholine-Dianeal® solution was provided by
Baxter R&D Europe, Nivelles, Belgium. This solution is a slightly
cloudy emulsion with 75% of the emulsion particles below 1 and
25% between 1 and 2 .t (510 mOsm/liter [7]). Dianeal® 4.25%
(purchased from Baxter Healthcare, Deerfield Illinois, USA)
served as control (480 to 490 mOsm/liter, measured in our
laboratory).
Animals
Twelve randomly bred female sheep (approximately 6 months old)
ranging in weight from 24 to 31 kg were used in this investigation.
Anesthesia and surgery
Pentothal sodium (Boehriger Ingelheim, Burlington, Ontario,
Canada) was given intravenously (15 to 25 mg/kg body wt) to
induce anesthesia. The sheep were then intubated with a Sheri-
dan/HVT tracheal tube (Sheridan Catheter Corp., Argyle, New
York, USA). Surgical and post-operative anesthesia were main-
tained with 1 to 2% fluothane (Halothane, Ayerst Laboratories,
New York City, New York, USA) in oxygen using a respiration
pump (Ventimeter Ventilater, Air Shields Inc., Hatboro, Penn-
sylvania, USA).
A small right lateral incision was made approximately 10 to 12
cm posterior to the last rib through which a Tenchkoff peritoneal
dialysis catheter equipped with two Dacron cuffs (Accurate Sur-
gical Instruments Corp., Toronto, Ontaio, Canada) was inserted
and the wound closed with suture silk. A catheter was placed in
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the right external jugular vein for sequential blood sampling. The
animals were allowed to recover for 24 hours in a metabolism
cage.
Experimental protocol
Prewarmed (37°C) phosphatidylcholine-DianeaU or Dianeal®
solution containing 25 Ci of '251-albumin was infused into the
peritoneal cavity at t = 0 hours. Hourly samples of peritoneal
dialysate fluid (5 ml) and blood (10 ml) were taken via the
peritoneal catheter and the intravenous jugular catheter respec-
tively for a period of six hours. At the end of each experiment (t
= 6 hours), the animals were sacrificed and any remaining fluid in
the peritoneal cavity was allowed to drain by gravity via the
peritoneal catheter into a graduated cylinder. This volume was
measured and three 10 ml samples were taken. Since there would
be an unknown volume of fluid remaining in the peritoneal cavity,
an additional 1,000 ml of saline was instilled. The cavity was then
opened and the contents thoroughly massaged to ensure that any
1251-albumin was mixed well with the added saline. An additional
three 10 ml samples were taken from three different regions of the
peritoneal cavity.
Each of the blood and peritoneal lavage samples was centri-
fuged for 15 minutes. To determine the concentration of radio-
activity (in cpm/ml), two 1.0 ml aliquots of the blood plasma,
dialysate and peritoneal lavage samples were placed in a multi-
channel gamma spectrometer (1282 CompuGamma CS, LKB
Wallac-Pharmacia, Turku, Finland) with appropriate window
settings and background subtraction. Six 1.0 ml aliquots of the
251-albumin solution instilled at t = 0 hour were also counted. To
ensure that the measured radioactivity in any sample was protein-
associated, a second set of aliquots was assayed after precipatation
with 10% TCA. Free or non-protein associated 1251 amounted to
less than 1% of the total radioactivity in any sample.
The blood plasma volume was determined for each sheep six
hours after the infusion of Dianeal® using dilution of Evan's blue
dye. The average blood plasma volume was 51.3 3.0 mI/kg.
Estimation of peritoneal volumes
To estimate the volume in the peritoneal cavity at t = 6 hours
after much of the fluid was drained into a graduated cylinder, a
dilution of a radioactive method was used as described earlier
[11]. In addition, we estimated the intraperitoneal volume (IPV)
at each time period, taking the loss of tracer from the peritoneal
cavity into account [16—18]. IPV can be calculated from the
difference in the amount of tracer infused and the amount of
tracer lost from the peritoneal cavity, divided by the tracer
concentration in the peritoneal cavity or:
V0C0 - [CFDR• t C) + V5C]
IPV1 (ml) = (Eq. 1)
where V0C0 is the volume (ml) and concentration of tracer
(cpmlml) instilled at the beginning of the period being monitored,
TDR is the fluid loss rate (ml/hr) based on tracer disappearance,
Cgeo is the geometric mean of the initial and final tracer concen-
trations in the peritoneal cavity (cpmlml), VsC is the product of
the volume and concentration of samples taken from the perito-
neal cavity and C is the concentration of radioactivity in the
peritoneal cavity.
To calculate the IPV1 at one hour:
V1C1 — [(TDR- 1- C®0) + VsC1]
IPV2 (ml) =
C2
TD (ml) = (V0C0 V6C6)ICgeo
tIPV (ml) = IPV + TD + SV
V0C13 — [(TDR -1- Cgeo) + VSC1 mini
IPV1 (ml) = (Eq. 2)
where Cimin is the tracer concentration at one minute ,and C1 is
the intraperitoneal tracer concentration at one hour. To calculate
the intraperitoneal volume at two hours:
(Eq. 3)
where V1C1 is the peritoneal volume and tracer concentration at
one hour and C2 is the intraperitoneal tracer concentration at
two hours. IVP at three to six hours was calculated similarly.
TDR is the fluid loss rate estimated from tracer disappearance
from the peritoneal cavity. Fluid loss (TD) can be calculated as:
(Eq. 4)
where V11 and C0 represent the volume of fluid instilled and the
concentration of radioactivity in the peritoneal cavity at t = 0
hours, V6 and C6 are the volumes and concentrations of tracer in
the peritoneal cavity at the end of the experiment (six hr), and
Cgeo is the geometric mean of the initial and final peritoneal tracer
concentration. The fluid loss rate based on tracer disappearance
was calculated as TD/6. Fluid loss (TD) could also be estimated
for each hour by substituting the appropriate volumes and con-
centrations of tracer at the beginning and end of each period
under investigation. To make these calculations we used intraper-
itoneal volumes estimated as described in equations I to 3.
Once the intraperitoneal volumes at each hour were calculated,
the net ultrafiltration volume (NUF) could be determined as the
difference between the volume in the peritoneal cavity at each
hour and the infused volume. A theoretical intraperitoneal vol-
ume (tIPV) that represents the volume that entered the perito-
neal cavity including an estimate of that fluid lost from the cavity
can be calculated as:
(Eq. 5)
where SV is the volume lost to sampling. The transcapillary
ultrafiltration (TCUF) can be estimated as tIPV —V0 (estimate of
volume movement into peritoneal cavity without fluid loss).
Calculation of lymph flow rates based on the appearance of
intraperitoneally administered tracer in the blood
Based on principles of mass balance, Flessner, Dedrick and
Reynolds [19] have estimated lymph flow rates from the perito-
neal cavity following the infusion of an hypertonic solution as:
(— K1 + KOUt)VB CB(tf) exp (K0tt)
C(ti) exp[—(Ki—K0t)td—1 (Eq.6)
where L. represents the lymph flow rate (ml/hr) from the
peritoneal cavity, C(ti) represents the concentration of tracer in
the peritoneal cavity at the beginning of the monitoring period,
VB represents the total plasma volume (ml) and Cfl(f) represents
the concentration of radioactivity (in cpm/ml) in the plasma
volume at the end of the monitoring period. The radioactivity in
blood is cumulative. As a consequence, in order to calculate the
amount of tracer in blood at a given time, the cpm/ml in the
previously collected sample was subtracted. The blood volume in
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each animal was estimated at the end of the experiment. We used
an Evan's blue dye dilution technique. K. is the coefficient of
elimination of 1251-HSA from the plasma. We have no evidence
that ICOU is affected by any of the procedures used in this study
and therefore have assumed that it is constant. Based on previous
experiments from our laboratory, K = 0.033/hr in sheep. K5 is
the slope of the peritoneal tracer concentration curve. We calcu-
lated K1 in each sheep between 0 and 6 hours and between each
of the one hour periods depending on the calculation in question.
Analysis of data
The data were assessed with analysis of variance, Wilcoxon
two-sample test or I-test as appropriate. P < 0.05 was significant.
Results
The concentration and recovery of 1251-albumin in the perito-
neal cavity are illustrated in Figure 1. Tracer concentration in the
peritoneal cavity (expressed as a percent of the instillate concen-
tration) declined as fluid moved into the cavity from the blood due
to the osmotic gradient (Fig. 1A). Significantly greater dilution of
the tracer was observed in the phosphatidylcholine-treated sheep
suggesting that more fluid entered the peritoneal cavity in this
group. Figure lB illustrates the recovery of tracer at each time in
the peritoneal cavity expressed as a percent of the injected dose.
Slightly more tracer left the cavity in the control animals; however,
these differences were not significant.
Phosphatidylcholine enhanced net ultrafiltration (NUF) at all
time points (Fig. 2). The data in Figure 2 employ the intraperi-
toneal volumes calculated as described in equations 1 to 3. In
addition, NUF was calculated at the end of the experiment (6 hrs)
using the volume drained from the cavity with an estimate of the
undrained volume based on a dilution of tracer method. NUF
calculated with the latter method rose to 30.3 3.8 ml/kg in the
phosphatidylcholine group and to 12.2 2.1 mI/kg in the control
animals (Table 1). The six hour values calculated either way
agreed closely.
Fluid loss, estimated from the disappearance of tracer from the
peritoneal cavity increased over time in both groups of animals
(Fig. 3). While the fluid loss in the phosphatidylcholine group was
less, this difference was not significant. We also calculated an
average fluid loss rate using the volumes drained from the cavity
at six hours with an estimate of the undrained volume employing
a dilution of tracer method. Fluid loss averaged 2.3 0.2 ml
hr' kg in the phosphatidylcholine-treated animals and 2.6
0.2 ml hiT' kg in the controls. The cumulative fluid loss over
six hours amounted to 15.8 1.6 ml/kg and 16.8 1.7 mI/kg in the
phosphatidylcholine and control groups, respectively (Table 1).
The blood recovery of '251-albumin expressed as a percentage
of injected dose is illustrated in Figure 4. The recovery of tracer in
blood was significantly less in the phosphatidylcholine group.
These values provided the basis of the lymph volume estimates
which are shown in Figure 5 and, as predicted from the recovery
data, the lymph volume drained from the peritoneal cavity was
significantly impaired by phosphatidylcholine. The volumes re-
moved by lymphatics were relatively constant in the phosphatidyl-
choline-treated sheep (ranging between 0.8 and 1.0 mI/kg),
whereas volumes drained in the controls increased from 1.3 to 2.0
mI/kg by three hours and then fell to 1.5 ml/kg at the end of the
experiment. The cumulative amount of liquid drained by lymphat-
0 1 2 3 4 5 6
Time, hours
Fig. 1. Concentration and recovety of 1251-albumin in the peritoneal cavity
in phosphatidylcholine-treated and control animals. (A) Concentration of
tracer expressed as a percentage of the instillate concentration. (B)
Recovery of tracer (product of concentration and volume) expressed as a
percentage of the injected dose. Symbols are: (0) control sheep; (•)
phosphatidylcholine-treated animals. A 2 factor ANOVA revealed that in(A), the percent instillate concentration was significantly different in the
treated and non-treated animals. There were no significant differences in
the tracer recoveries in the two groups (B).
ics was estimated as 5.5 1.1 ml/kg and 10.3 1.0 ml/kg in the
phosphatidylcholine-treated and control sheep, respectively. The
average lymph flow rates over six hours were calculated to be 0.9
0.2 ml hiT' kg' in the phosphatidylcholine group and 1.7
0.1 ml hiT' kgt in the controls.
Table 1 illustrates a summary of the volume data. At six hours,
the calculated intraperitoneal volumes (equations 1 to 3) were
81.0 3.8 ml/kg and 62.1 2.2 mI/kg in the animals receiving
phosphatidylcholine or dialysate alone. These values agree closely
with those estimated from the volumes drained from the cavity at
six hours and an estimate of the undrained volume employing a
dilution of tracer method. Using the latter method volumes were
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E
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V
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Control Phosphatidyicholine
group groupN=6 N=6
mi/kg mi/kg
V0 49.9 0.2 50.7 0.4
IPV 62.1 2.2a 81.0 3.8a
NUF 12.2 2.1 30.3 3.8
TD 16.8 1.7 15.8 1.6
Lpc 10.3 1.0 5.5 1.P
tIPV 77.5 1.8 94.6 3.6a
TCUF 27.6 1.5 43.8 3.4
Animal weights kg 29.5 1.5 26.7 0.8
Abbreviations are: V0, instilled volume; IVP, calculated intraperitoneal
volume including correction for sampling; NUF, net ultrafiltration; TD,
cumulative fluid loss calculated from tracer disappearance over six hours;
Lpc, cumulative lymph volume removed based on tracer recovery in blood
over six hours; tIVP, theoretical intraperitoneal volume calculated as
IPV + TD; TCUF, transcapillaiy ultrafiltration calculated as tIPV — V0.
Groups are significantly different
81.3 3.9 mI/kg and 62.4 2.2 mI/kg in the phosphatidyicholine
and controls, respectively. In both cases, IPV was significantly
greater in the phosphatidyicholine-treated animals.
The theoretical intraperitoneal volumes (tIPV) (that is, the
estimated volumes in the absence of fluid loss) were also signifi-
cantly greater in the phosphatidyicholine group (94.6 3.6 vs.
77,5 1.8 mi/kg in the controls). Calculations of the transcapillary
ultrafiltration volumes (TCUF) suggested that phosphatidyicho-
line facilitated the movement of fluid from the bloodstream into
the peritoneal cavity. TCUF in the animals receiving phosphati-
dyicholine was estimated to be 43.8 3.4 ml/kg, whereas in the
control sheep it was 27.6 1.5 mI/kg. These values were signifi-
cantly different.
Table 2 illustrates the total tracer recovery data for these
E
LI
z
35
30
25
20
15
10
5
0
3.5
3.0
2.5
2.0
1.5
1.0
0 1 2 3 4 5 6
Time, hours
Fig. 2. Net ultrafiltration in phosphatidyicholine-treated (•) and control(0) animals. A 2 factor ANOVA revealed that net ultrafiltration was
significantly different in the treated and non-treated groups.
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Fig. 3. Fluid loss calculated from tracer disappearance in phosphatidylcho-
line-treated () and control (0) animals. A 2 factor ANOVA revealed no
significant differences in fluid loss in the treated and non-treated groups.
Table 1. Analysis of volumes in the peritoneal cavity at six hours 1 8
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Fig. 4. Recovery of '251-albumin in blood e7cpressed as a percentage of
injected dose in phosphatidylcholine-treated (•) and control (0) animals. A
2 factor ANOVA revealed that the recovery of tracer in the blood was
significantly different in the treated and non-treated groups.
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Table 2. Recovery of '251-albumin at six hours (percent of injected
dose)
Fig. 5. Lymph volume removed from peritoneal cavity calculated from the
recovery of tracer in the blood in phosphatidyicholine-treated (•) and control
(0) animals. A 2 factor ANOVA revealed that lymph volumes removed
from the peritoneal cavity in the treated and non-treated groups were
significantly different. The individual points at 2, 3, 4 and 5 hours, but not
at 1 and 6 hours were significantly different.
experiments. Less tracer was recovered in the phosphatidylcho-
line-treated group (88.0 1.2 vs. 91.8 1.7 in controls), but these
values were not significantly different. Similarly, there were no
significant differences in 1251-albumin recoveries in the peritoneal
cavity. Blood recoveries were significantly higher in the control
animals.
Discussion
Several pharmacologic agents have been added to dialysis
solution in the hopes that they will enhance ultrafiltration. These
include the cholinergic agents neostigmine [20, 21] and phosphati-
dylcholine [5—7, 22, 23]. One of the most promising agents is
phosphatidylcholine. In 1985, Grahame et al [1] detected the
presence of surface active material (phospholipid) in the perito-
neal effluent of CAPD patients. Other studies have since estab-
lished that phosphatidyicholine represents 81% of the phospho-
lipid present [4]. Phosphatidylcholine is a substrate locally
produced in the peritoneal cavity and it appears to play an
important role in the normal physiology of serosal cavities [24].
Several groups reported that the level of phospholipid in the
dialysis effluent decreases with time on CAPD, and it is lower still
in patients with poor ultrafiltration and in patients with peritonitis
[2—4]. These observations led to the speculation that an improve-
ment in the phospholipid level might be accompanied by an
improvement in ultrafiltration. Recently, Krack et al [7] reported
that even though premixed phosphatidylcholine dialysis solution
had a slightly higher osmolality (4%) than the comparable solu-
tion without phosphatidylcholine, the effect of this agent on
ultrafiltration was more than that expected from the osmolality
factor alone. With the phosphatidylcholine solutions, the patient's
Control
groupN=6
Phosphatidylcholine
groupN=6
Blood 16.0 1.3 7.4 1.Sa
Peritoneal cavity 75.8 2.1 80.7 2.0
Total recovery of tracer 91.8 1.7 88.0 1.2
2.4
2.0
1.6
1.2
E
a)
E
0>
0.
E>'
-J 0.8
a Groups are significantly different
glucose load per day can be reduced to achieve equal ultrafiltra-
tion. A major advantage of phosphatidyicholine is that it appears
to increase ultrafiltration without the potential deleterious effects
associated with dextrose-based dialysis solutions of increasing
0.4
osmolality.
Reports on the clinical use of phosphatidylcholine in peritoneal
dialysis patients have yielded conflicting results [24]. Several0.0 — T investigators demonstrated that administration of phosphatidyl-
0 1 2 3 4 5 6 choline either intraperitoneally, intravenously or orally, improved
peritoneal ultrafiltration [5—7]. In contrast, other groups claimed
Time, hours that phosphatidylcholine had no effect on ultrafiltration [22, 23].
Different phosphatidylcholine preparations and the inevitable
clinical variables in each of the patients make interpretations of
these results difficult. To complicate matters, the administration
of phosphatidylcholine causes discomfort in some patients [22],
raising the possibility of undesirable side effects. Gagnon et al [25]
tested the toxicity of phosphatidyicholine and concluded that
phosphatidylcholine was toxic for peritoneal cells when combined
with dialysis solution. Breborowicz et al [26] demonstrated that
phosphatidylcholine had toxic effects on mesothelial cells in tissue
culture.
Clearly, the use of phosphatidylcholine in dialysis requires
further study given its potential benefit to ultrafiltration. Two
theories have been advanced to explain how phosphatidylcholine
may increase ultrafiltration under some circumstances, It may
facilitate the movement of water and solutes from the vascular
space into the peritoneal cavity or, it may act by reducing
lymphatic drainage.
In the experiments reported here, phosphatidylcholine affected
both the movement of vascular fluid into the cavity and the
removal of liquid by lymphatics. In terms of ultrafiltration, some
of phosphatidylcholine's effect may be due to the greater osmo-
lality of the solution relative to the control Dianeala solution.
However, one might predict that this effect is small since the
osmolality of the two solutions is very close (510 vs. 480 to 490
mOsm/liter). Calculations of NUF and TCUF in the sheep
experiments indicate significant increases in fluid movement into
the peritoneal cavity with phosphatidylcholine and it appears
unlikely that this effect is due to osmolality alone.
Phosphatidyicholine, like phospholipid in lung, has surfactant
properties and can reduce surface tension. Rat mesothelium has
an almost equal capacity as rat lung for the synthesis of phosphati-
dylcholine [27]. Breborowicz et at [8] hypothesized that part of the
action of phosphatidyicholine may relate to its charge effect. The
positively charged choline may bind to the negatively charged
mesothelial surface. Leak [28] demonstrated that a high density of
anionic sites exists on the surface of the intercellular clefts of
subdiaphragmatic mesothelium and lymphatic endothelium.
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Phosphatidyicholine may form a water repellent surface which
removes water from the intervillar spaces and reduces the thick-
ness of the unstirred layers of fluid on the surface of the
mesothelium. This may facilitate the movement of solutes from
the vascular to the mesothelial side of the membrane. On the
other hand, the hydrophobic fatty acid tails of the phosphatidyl-
choline facing the serous cavity may impair the movement of
water from the mesothelial to the vascular side of the peritoneal
membrane.
Mactier et at [9, 20] suggested that phosphatidyicholine in-
creased ultrafiltration by reducing lymphatic drainage rather than
by increasing transcapiliary flow. Their experiments in rats dem-
onstrated that there was little uptake of Indian ink by the
peritoneal lymphatics when phosphatidylcholine was injected into
the peritoneal cavity. Similarly, in humans phosphatidylchoiine
enhanced ultrafiltration and this effect was attributed to suppres-
sion of lymphatic drainage [5]. This agent may decrease peritoneal
lymphatic drainage by reducing the patency of the subdiaphrag-
matic stomata.
Our work also demonstrated that phosphatidyicholine inhibited
lymph flow (approximately 50%). However, this effect may not be
the major contributor to the enhanced NUF in the phosphatidyi-
choline-treated animals, One would predict that a depressed
lymph flow would be reflected by a reduction of the fluid loss over
the course of the experiment. We did observe a slight reduction in
fluid loss in the phosphatidyicholine-treated sheep, but these
differences were not significant. Based on the data illustrated in
Table 1, total fluid loss in the phosphatidylcholine group was
reduced by 1.0 mI/kg while the loss through lymphatics was
suppressed by 4.8 mI/kg.
Since total fluid loss was much less affected by phosphatidyl-
choline than lymph drainage, one might speculate that the loss of
liquid via routes other than the lymphatics may have increased to
keep total fluid losses at roughly the same level. Perhaps more
tracer moved from the peritoneal cavity into the tissues surround-
ing the cavity following the administration of phosphatidyicholine.
The importance of this phenomenon in estimating lymph flow
rates has been emphasized by Flessner and colleagues [29, 30].
In our experiments, tracer depostion could be due to the
greater intraperitoneal pressures that one expects would occur in
the phosphatidyicholine-treated animals due to the increase in
intraperitoneal volumes. In the studies reported here, intraperi-
toneal volumes at six hours averaged 2139 161 ml in the
phosphatidyicholine group and 1830 127 ml in the controls, a
difference of 309 ml. In a previous report we published the
pressure-volume relationships in the sheep peritoneal cavity [13].
Based on an increase of 309 ml in the phosphatidyicholine-treated
sheep, we estimate that intraperitoneal pressures would increase
approximately 1 cm H2O. Flessner, Parker and Sieber [31]
reported that intraperitoneal pressures affected fluid loss rates but
not lymph flow rates. Whether a 1 cm H20 intraperitoneal
pressure increase is enough to account for the greater non-
lymphatic fluid loss in our phosphatidyicholine-treated animals is
not known.
If fluid loss by a non-lymphatic route was increased such that
the total liquid removed from the peritoneal cavity remained
approximately the same, the total tracer recovery data illustrated
in Table 2 would be expected to reflect greater tracer loss (that is,
unaccounted for tracer) in the phosphatidylcholine-treated ani-
mals. The total recovery of 1251-albumin in the control and treated
animals was 91.8 and 88.0, respectively. This 3.8% difference in
recoveries was not significant (given the relatively small number of
animals used in this study). However, one might argue that a loss
of 3.8% of the instilled tracer in the tissues surrounding the cavity
could account for the volume differences between estimates of
fluid loss and lymph drainage.
The fluid loss (estimated from tracer disappearance was 16.8
mi/kg in the controls. Lymph drainage accounted for 10.3 mI/kg.
In the phosphatidyichoiine-treated sheep, fluid loss was 15.8 mi/kg
of which 5.5 mi/kg was removed by lymphatics. Therefore, the
difference between the total fluid lost and the lymph drainage
amounted to 6.5 mi/kg in the controls versus 10.3 mi/kg in the
phosphatidyichoiine-treated sheep. These values may represent
the volumes removed from the peritoneai cavity by a non-
lymphatic route. Subtracting 6.5 from 10.3 yieids 3.8 mi/kg. If this
reasoning is correct, the 3.8 mI/kg represents the increased
volume that would have to leave the peritoneai cavity via a
non-iymphatic route in the phosphatidyicholine group in order to
keep the total fluid lost from the cavity roughly constant in the two
groups. Based on equation 4 the hypothetical amount of tracer
that would have to be removed from the peritoneal cavity can be
caiculated to account for a 3.8 mi/kg greater volume loss in the
treated animals, An estimated 5.3% of the injected radioactivity
must be lost from the peritoneai cavity to account for the 3.8
mi/kg. A 3.8% difference was observed in total recoveries in the
two groups. These numbers are close enough to suggest the
possibility that phosphatidyichoiine treatment resulted in greater
deposition of 1251-albumin in the tissues surrounding the perito-
neai cavity.
At this point, some comment should be made concerning the
method used to calculate lymph drainage of the peritoneal cavity.
This remains a contentious issue. Several investigators estimate
lymph drainage as the disappearance rate of a lymph flow marker
from the peritoneai cavity and have reported that phosphatidyl-
choline depressed lymph drainage of the peritoneal cavity, [5, 9,
20]. Several groups compared lymph drainage using this method
with that empioyed in this study, that is, the appearance of
intraperitoneaiiy administered tracer in the blood [14, 17, 31].
Lymph flows estimated from the appearance of tracer in the
bloodstream were always less than those estimated from the
disappearance of the tracer moiecuie. This difference may be due
to the movement of liquid and the lymph flow marker into the
tissues surrounding the peritoneai cavity with the tracer and fluid
reentering the blood at different rates [reviewed in 32].
How would the conclusions we have made above differ if we
were to use the tracer disappearance technique to estimate lymph
drainage? We wouid assume that au fluid lost from the peritoneal
cavity escaped by lymphatics. Based on this approach, the data
would suggest that phosphatidyicholine had little impact on
lymphatic drainage and we would conciude that its greatest effect
was to promote transcapiiiary ultrafiltration. Therefore, despite
the fact that these methods of calculation provide a different
perspective on the role of lymphatics, the major conclusion of the
study is the same.
In humans [5] and rats [9, 20], phosphatidylcholine significantly
reduced tracer disappearance from the peritoneai cavity. We can
only assume that species differences exist since the tracer disap-
pearance in sheep was not significantiy affected by phosphatidyl-
choiine.
In summary, one must be cautious when extranoiatine studies in
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sheep to humans. One major difference between the animal
model and peritoneal dialysis patients is that the animals have
normal kidney function and it is not clear how kidney disease may
affect lymphatic drainage of the peritoneal cavity. Nonetheless, in
physiological terms, the addition of phosphatidyicholine to dialy-
sate significantly improved net ultrafiltration. Phosphatidylcholine
suppressed lymph drainage of the peritoneal cavity, but this effect
did not appear to contribute significantly to peritoneal volume
dynamics since the total fluid loss was very similar in the phos-
phatidyicholine-treated and non-treated animals. The data sup-
port the hypothesis that the main effect of phosphatidyicholine is
to facilitate the movement of liquid from the blood into the
peritoneal cavity.
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